Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

L. Mezquita; Amparo Benito; Alberto Ruano-Raviña; Javier Zamora; Maria Eugenia Olmedo; P. Reguera; Ainhoa Madariaga; María Villamayor; Silvia Patricia Cortez; Luis Gorospe; Almudena Santón; Sagrario Mayoralas; Raúl Hernanz; Alberto Cabañero; Edouard Auclin; Alfredo Carrato; P. Garrido

doi:10.1016/j.cllc.2019.04.009

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

L. Mezquita, Amparo Benito, Alberto Ruano-Raviña, Javier Zamora, Maria Eugenia Olmedo, P. Reguera, Ainhoa Madariaga, María Villamayor, Silvia Patricia Cortez, Luis Gorospe, Almudena Santón, Sagrario Mayoralas, Raúl Hernanz, Alberto Cabañero, Edouard Auclin, Alfredo Carrato, P. Garrido^*

^*Corresponding author for this work

Metabolism and Systems Research

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

Background: Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations. Patients and Methods: We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively. Results: Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm. Conclusion: The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies. Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.

Original language	English
Pages (from-to)	305-312.e3
Journal	Clinical Lung Cancer
Volume	20
Issue number	4
DOIs	https://doi.org/10.1016/j.cllc.2019.04.009
Publication status	Published - Jul 2019

Bibliographical note

Funding Information:
The authors thank Sarah MacKenzie, PhD, for English-language editing. They thank the team of the Medical Oncology Department and the Thoracic Oncology Committee, at the Ramón y Cajal Hospital (Madrid, Spain).

Publisher Copyright:
© 2019 Elsevier Inc.

Keywords

Driver oncogene
NSCLC
Radioactivity
Radon gas

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.cllc.2019.04.009

Cite this

Mezquita, L., Benito, A., Ruano-Raviña, A., Zamora, J., Olmedo, M. E., Reguera, P., Madariaga, A., Villamayor, M., Cortez, S. P., Gorospe, L., Santón, A., Mayoralas, S., Hernanz, R., Cabañero, A., Auclin, E., Carrato, A., & Garrido, P. (2019). Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients. Clinical Lung Cancer, 20(4), 305-312.e3. https://doi.org/10.1016/j.cllc.2019.04.009

@article{cfd75e035f044c738200bb1c2114098a,

title = "Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients",

abstract = "Background: Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations. Patients and Methods: We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively. Results: Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm. Conclusion: The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies. Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.",

keywords = "Driver oncogene, NSCLC, Radioactivity, Radon gas",

author = "L. Mezquita and Amparo Benito and Alberto Ruano-Ravi{\~n}a and Javier Zamora and Olmedo, {Maria Eugenia} and P. Reguera and Ainhoa Madariaga and Mar{\'i}a Villamayor and Cortez, {Silvia Patricia} and Luis Gorospe and Almudena Sant{\'o}n and Sagrario Mayoralas and Ra{\'u}l Hernanz and Alberto Caba{\~n}ero and Edouard Auclin and Alfredo Carrato and P. Garrido",

note = "Funding Information: The authors thank Sarah MacKenzie, PhD, for English-language editing. They thank the team of the Medical Oncology Department and the Thoracic Oncology Committee, at the Ram{\'o}n y Cajal Hospital (Madrid, Spain). Publisher Copyright: {\textcopyright} 2019 Elsevier Inc.",

year = "2019",

month = jul,

doi = "10.1016/j.cllc.2019.04.009",

language = "English",

volume = "20",

pages = "305--312.e3",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "4",

}

Mezquita, L, Benito, A, Ruano-Raviña, A, Zamora, J, Olmedo, ME, Reguera, P, Madariaga, A, Villamayor, M, Cortez, SP, Gorospe, L, Santón, A, Mayoralas, S, Hernanz, R, Cabañero, A, Auclin, E, Carrato, A & Garrido, P 2019, 'Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients', Clinical Lung Cancer, vol. 20, no. 4, pp. 305-312.e3. https://doi.org/10.1016/j.cllc.2019.04.009

TY - JOUR

T1 - Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

AU - Mezquita, L.

AU - Benito, Amparo

AU - Ruano-Raviña, Alberto

AU - Zamora, Javier

AU - Olmedo, Maria Eugenia

AU - Reguera, P.

AU - Madariaga, Ainhoa

AU - Villamayor, María

AU - Cortez, Silvia Patricia

AU - Gorospe, Luis

AU - Santón, Almudena

AU - Mayoralas, Sagrario

AU - Hernanz, Raúl

AU - Cabañero, Alberto

AU - Auclin, Edouard

AU - Carrato, Alfredo

AU - Garrido, P.

N1 - Funding Information: The authors thank Sarah MacKenzie, PhD, for English-language editing. They thank the team of the Medical Oncology Department and the Thoracic Oncology Committee, at the Ramón y Cajal Hospital (Madrid, Spain). Publisher Copyright: © 2019 Elsevier Inc.

PY - 2019/7

Y1 - 2019/7

N2 - Background: Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations. Patients and Methods: We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively. Results: Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm. Conclusion: The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies. Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.

AB - Background: Radon gas is the leading cause of lung cancer in the nonsmoking population. The World Health Organization (WHO) recommends indoor concentrations of < 100 Bq/m³. Several molecular alterations have been described in non–small-cell lung cancer (NSCLC), mainly in nonsmokers, with no risk factors identified. We studied the role of indoor radon in NSCLC patients harboring specific driver alterations. Patients and Methods: We assessed the radon concentration from EGFR-, BRAF-mutated (m), and ALK-rearranged (r) NSCLC patients measured by an alpha-track detector placed in their homes between September 2014 and August 2015. Clinical characteristics were collected prospectively, and pathologic samples were reviewed retrospectively. Results: Forty-eight patients were included (36 EGFRm, 10 ALKr, 2 BRAFm). Median radon concentration was 104 Bq/m³ (IQR 69-160) overall, and was 96 Bq/m³ (42-915) for EGFRm, 116 (64-852) for ALKr, and 125 for BRAFm, with no significant differences. Twenty-seven patients (56%) had indoor radon above WHO recommendations, 8 (80%) of 10 ALKr, 2 (100%) of 2 BRAFm, and 17 (47%) of 36 EGFRm. Conclusion: The median indoor radon concentration was above the WHO recommendations, with no differences between EGFR, ALK, and BRAF patients. Concentrations above the WHO recommendations were most common with ALKr and BRAFm. These findings should be validated in larger studies. Radon is the first cause of lung cancer in nonsmokers according to the World Health Organization (WHO), which recommends not exceeding 100Bq/m³ in homes. No risk factor has yet been identified for non–small-cell lung cancer (NSCLC) harboring driver alterations, mainly nonsmokers. We found a median concentration of 104 Bq/m³, above the WHO recommendation in EGFR-mutated, BRAF-mutated, and ALK-rearranged NSCLC patients, with no differences between them.

KW - Driver oncogene

KW - NSCLC

KW - Radioactivity

KW - Radon gas

UR - http://www.scopus.com/inward/record.url?scp=85066147595&partnerID=8YFLogxK

U2 - 10.1016/j.cllc.2019.04.009

DO - 10.1016/j.cllc.2019.04.009

M3 - Article

C2 - 31151782

AN - SCOPUS:85066147595

SN - 1525-7304

VL - 20

SP - 305-312.e3

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 4

ER -

Indoor Radon in EGFR- and BRAF-Mutated and ALK-Rearranged Non–Small-Cell Lung Cancer Patients

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this